These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 35103817)
1. A novel approach to calculating the kinetically derived maximum dose. Burgoon LD; Fuentes C; Borgert CJ Arch Toxicol; 2022 Mar; 96(3):809-816. PubMed ID: 35103817 [TBL] [Abstract][Full Text] [Related]
2. Kinetically-derived maximal dose (KMD) indicates lack of human carcinogenicity of ethylbenzene. Burgoon LD; Borgert CJ; Fuentes C; Klaunig JE Arch Toxicol; 2024 Jan; 98(1):327-334. PubMed ID: 38059960 [TBL] [Abstract][Full Text] [Related]
3. Use of the kinetically-derived maximum dose concept in selection of top doses for toxicity studies hampers proper hazard assessment and risk management. Heringa MB; Cnubben NHP; Slob W; Pronk MEJ; Muller A; Woutersen M; Hakkert BC Regul Toxicol Pharmacol; 2020 Jul; 114():104659. PubMed ID: 32334038 [TBL] [Abstract][Full Text] [Related]
4. Principles of dose-setting in toxicology studies: the importance of kinetics for ensuring human safety. Borgert CJ; Fuentes C; Burgoon LD Arch Toxicol; 2021 Dec; 95(12):3651-3664. PubMed ID: 34623454 [TBL] [Abstract][Full Text] [Related]
5. Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment. Tan YM; Barton HA; Boobis A; Brunner R; Clewell H; Cope R; Dawson J; Domoradzki J; Egeghy P; Gulati P; Ingle B; Kleinstreuer N; Lowe K; Lowit A; Mendez E; Miller D; Minucci J; Nguyen J; Paini A; Perron M; Phillips K; Qian H; Ramanarayanan T; Sewell F; Villanueva P; Wambaugh J; Embry M Regul Toxicol Pharmacol; 2021 Dec; 127():105070. PubMed ID: 34718074 [TBL] [Abstract][Full Text] [Related]
6. Afidopyropen: Challenges and impact of a toxicokinetic study designed to identify a point of inflection from dose-proportionality. Loccisano AE; Freeman E; Riffle B; Doi A; Frericks M; Fegert I; Fabian E Regul Toxicol Pharmacol; 2021 Aug; 124():104962. PubMed ID: 34019964 [TBL] [Abstract][Full Text] [Related]
7. Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs. Saganuwan SA BMC Pharmacol Toxicol; 2021 Oct; 22(1):57. PubMed ID: 34635182 [TBL] [Abstract][Full Text] [Related]
8. Legitimacy of the stochastic Michaelis-Menten approximation. Sanft KR; Gillespie DT; Petzold LR IET Syst Biol; 2011 Jan; 5(1):58. PubMed ID: 21261403 [TBL] [Abstract][Full Text] [Related]
9. Exact and approximate solutions for the decades-old Michaelis-Menten equation: Progress-curve analysis through integrated rate equations. Goličnik M Biochem Mol Biol Educ; 2011; 39(2):117-25. PubMed ID: 21445903 [TBL] [Abstract][Full Text] [Related]
10. The Relationship Between Internal and External Dose: Some General Results Based on a Generic Compartmental Model. Slob W; Zeilmaker MJ; Hoogenveen RT Toxicol Sci; 2020 Sep; 177(1):60-70. PubMed ID: 32514576 [TBL] [Abstract][Full Text] [Related]
11. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation. Cheng HY; Jusko WJ Pharm Res; 1988 Mar; 5(3):156-64. PubMed ID: 3244627 [TBL] [Abstract][Full Text] [Related]
12. Estimating kinetic constants in the Michaelis-Menten model from one enzymatic assay using Approximate Bayesian Computation. Tomczak JM; Węglarz-Tomczak E FEBS Lett; 2019 Oct; 593(19):2742-2750. PubMed ID: 31283008 [TBL] [Abstract][Full Text] [Related]
13. Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals. Terry C; Hays S; McCoy AT; McFadden LG; Aggarwal M; Rasoulpour RJ; Juberg DR Regul Toxicol Pharmacol; 2016 Mar; 75():89-104. PubMed ID: 26472101 [TBL] [Abstract][Full Text] [Related]
14. Beyond the Michaelis-Menten: Bayesian Inference for Enzyme Kinetic Analysis. Hong H; Choi B; Kim JK Methods Mol Biol; 2022; 2385():47-64. PubMed ID: 34888715 [TBL] [Abstract][Full Text] [Related]
15. Toxicokinetics in the National Toxicology Program. Goehl TJ NIDA Res Monogr; 1997; 173():273-304. PubMed ID: 9260193 [TBL] [Abstract][Full Text] [Related]
16. Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. Grevel J; Post BK; Kahan BD Clin Pharmacol Ther; 1993 Jun; 53(6):651-60. PubMed ID: 8513657 [TBL] [Abstract][Full Text] [Related]
17. Sigmoidal substrate saturation curves in Michaelis-Menten mechanism as an artefact. Fischer E; Keleti T Acta Biochim Biophys Acad Sci Hung; 1975; 10(3):221-7. PubMed ID: 1211106 [TBL] [Abstract][Full Text] [Related]
18. Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors. Pelekis M; Nicolich MJ; Gauthier JS Risk Anal; 2003 Dec; 23(6):1239-55. PubMed ID: 14641898 [TBL] [Abstract][Full Text] [Related]
19. Parameter estimation using a direct solution of the integrated Michaelis-Menten equation. Goudar CT; Sonnad JR; Duggleby RG Biochim Biophys Acta; 1999 Jan; 1429(2):377-83. PubMed ID: 9989222 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic models: parameterizing the hill equation, Michaelis-Menten, the logistic curve, and relationships among these models. Reeve R; Turner JR J Biopharm Stat; 2013 May; 23(3):648-61. PubMed ID: 23611201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]